Skip to main content

Table 3 Demographic Data and Pharmacokinetic Parameter Estimates for Montelukast

From: Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: Effect on eosinophil density and activation in relation to pharmacokinetics

Subject No. Age
(yr)
Dose
(mg/kg)
Weight
(kg)
Ka
(1/hr)
Vd/F
(L/kg)
Kel
(1/hr)
1 13 0.188 53.3 0.532 0.08 0.334
3 14 0.166 60.2 0.577 0.06 0.399
5 10 0.293 34.1 0.609 0.14 0.475
7 14 0.125 80.1 0.545 0.09 0.354
8 13 0.272 36.7 0.555 0.11 0.386
9 9 0.22 45.4 0.498 0.11 0.293
10 11 0.305 32.8 0.553 0.13 0.396
11 14 0.14 71.2 0.554 0.10 0.375
12 11 0.305 32.8 0.507 0.14 0.354
13 16 0.176 56.9 0.544 0.14 0.401
14 15 0.187 53.6 0.535 0.13 0.369
15 15 0.169 59.1 0.570 0.10 0.396
17 10 0.173 57.7 0.538 0.11 0.355
19 11 0.152 65.6 0.546 0.08 0.353
20 13 0.223 44.8 0.548 0.13 0.394
21 15 0.115 87.3 0.565 0.11 0.395
22 14 0.19 52.6 0.605 0.08 0.424
23 15 0.123 81.2 0.538 0.09 0.345
Mean (SD) 12.9 (2.1) 0.20 (0.06) 55.9 (16.7) 0.55 (0.03) 0.11 (0.02) 0.38 (0.04)